(Q44066305)

29 November 2017

Pregabalin abuse and dependence in Germany: results from a database query (English)

1 reference

Carlos Schönfeldt-Lecuona

29 November 2017

0 references

0 references

series ordinal

5

object named as

Carlos Schönfeldt-Lecuona

1 reference

29 November 2017

Roland W Freudenmann

2

0 references

Maximilian Gahr

series ordinal

1

object named as

Maximilian Gahr

1 reference

29 November 2017

3

Christoph Hiemke

1 reference

29 November 2017

Makus A Kölle

4

1 reference

29 November 2017

5 January 2013

1 reference

European Journal of Clinical Pharmacology

29 November 2017

1 reference

29 November 2017

69

1 reference

29 November 2017

6

1 reference

29 November 2017

1335-1342

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-012-1464-6

29 November 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin for the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

A randomized, placebo-controlled study of pregabalin for postoperative pain intensity after laparoscopic cholecystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin treatment of posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin in the discontinuation of long-term benzodiazepines' use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin in benzodiazepine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Efficacy and safety of pregabalin in alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Drug safety evaluation of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin and its potential for abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin abuse, dependence, and withdrawal: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin in clinical psychiatry and addiction: pros and cons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Five-Factor Model personality profiles of drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

The mechanisms of action of gabapentin and pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Gabapentin: pharmacology and its use in pain management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Auxiliary subunits: essential components of the voltage-gated calcium channel complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Benzodiazepines revisited--will we ever learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Clinical pharmacokinetics of pregabalin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1464-6

Potential for pregabalin abuse or diversion after past drug-seeking behavior.

21 January 2018

1 reference

12 December 2020

[The prescription registry and abuse of pregabalin]

1 reference

12 December 2020

Pregabalin for chronic prostatitis

1 reference

12 December 2020

1 reference

12 December 2020

Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.

1 reference

12 December 2020

[Pregabalin--a drug with abuse potential?].

1 reference

12 December 2020

Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression.

1 reference

12 December 2020

Gabapentin and pregabalin: abuse and addiction

1 reference

12 December 2020

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

1 reference

12 December 2020

Gabapentin is not a GABAB receptor agonist

1 reference

12 December 2020

Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice

1 reference

12 December 2020

Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin

1 reference

12 December 2020

[Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes]

1 reference

12 December 2020

Earlier discovery of pregabalin's dependence potential might have been possible

1 reference

12 December 2020

Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine

1 reference

12 December 2020

Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats.

1 reference

12 December 2020

10.1007/S00228-012-1464-6

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

23292158